The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.
Rising tension and missile warfare at Korean peninsula putting world at crossroad of possible dangerous nuclear disaster. A 10-kiloton detonation to city population like Virginia (with a population of 2 million) can bring more than 270,000 Acute Radiation Syndrome incidents. Hence major federal governments of the world are keeping them prepared for the treatment.
Some of the leading players in the market have been assessed using three major parameters such as Product portfolio, Government funding and Market Dominance. In addition, few other parameters considered include financials, technological advancements and product reviews from end users. Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. Their range of products developed has application from Acute Radiation Syndrome to Nerve gas exposure.
“Optimal Price Point (OPP) for Radiation Toxicity Treatment Products”
Estimated Average Acute Radiation Syndrome Treatment cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
The pricing strategies being adopted by industry participants is largely influenced by factors such as R&D costs, government funding and demand in the market. Technological advancements in the field of Biologics will also play an important role in shaping pricing trends in the market over the forecast period.
Based on the radiation type, the market has been segmented into ionizing and non-ionizing. The market is further segmented by disease and treatment type. Based on type of exposure, market is segmented to Acute and Chronic Radiation Syndrome. Market is dominated by Acute Radiation Syndrome. By disease type, G.I syndrome contributes maximum % to overall revenue. By treatment type, Bone marrow transplant represents the maximum % to overall revenue.
Acute exposure to ionizing radiation triggers apoptotic cell death of hematopoietic stem and progenitor cells (HSPCs), leaving the individual prone to infection and hemorrhage. Therefore, the administration of antiapoptotic cytokines and colony-stimulating factors represents an important aspect of treatment of a patient with acute radiation syndrome. Transfusion of whole blood or peripheral blood mononuclear cells delivering myeloid progenitor cells has been proposed as a “bridging therapy” in patients who have suffered a severe but not complete injury to the hematopoietic system. Transplanted progenitor cells might provide the necessary granulocytes, red blood cells and platelets during the critical period of bone marrow failure.
We have detail pipeline analysis in the report including drug name, Organization, Mechanism of action and Status. There are different theories propounded regarding the mechanisms of radiation protection, such as free radical scavenging, calcium channel blocking, inhibition of lipid peroxidation, enhancement of DNA repair and stimulation of stem cell proliferation are considered important.
Overall R&D activities revolve around-
Clinical testing of potential Radioprotective Agents could be initiated only after the radioprotective efficacy is convinced by preclinical studies that simulate, as much as possible, the conditions under which the agent will be used clinically.
U.S being the largest market because of its sensitive military activities and threat perception. It accounted for xx % of the market share in 2016 ($ x,xxx Million) and will keep growing to occupy 54% of the global market. Middle East market in decline trend due to moving out of U.S troops and reducing threat perception. In Europe, UK, Germany, France represent significant market
In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.
Growth Drivers & Restraints
Some of the leading market drivers are Nuclear Attack Threat Perception, Increasing Use of Radiation Therapy, Nuclear Medicine in the Treatment and Diagnosis of Diseases and Increasing Government Support for Research and Development. Key market challenges are High Cost of Treatment, Shortage of Trained Professional and Accessibility of Treatment.
Top Players & Company Share
Prominent companies operating in the global chiral chromatography columns market include Osiris Therapeutics Inc., Nanotherapeutics Inc., NeoStem Inc., Gamida Cell Ltd, Cantex Pharmaceuticals Inc., Aeolus Pharmaceuticals, Cleveland BioLabs Inc., Tonix Pharmaceuticals Holding Corp, Onconova Therapeutics Inc.
Radiation Toxicity Treatment Market by “Type of Exposure” (Revenue, USD Million, 2014- 2024)
- Acute radiation syndrome (ARS) (Single large exposure)
- Chronic Radiation Syndrome (Small exposures spread over time)
Radiation Toxicity Treatment Market by “Radiation Type” (Revenue, USD Million, 20124- 2024)
- Ionizing (Alpha/Beta/Gama)
Radiation Toxicity Treatment Market by “Disease Type” (USD Million) (Revenue, USD Million, 20124- 2024)
- Bone Marrow Syndrome (Hematopoietic)
- Gastrointestinal Syndrome (GI)
- Cardiovascular (CV)
- Central Nervous System (CNS) Syndrome
Radiation Toxicity Treatment Market Regional Outlook (Revenue, USD Million, 20124- 2024)
- North America
- Latin America
- Asia pacific
- Middle East & Africa
- Saudi Arabia
- South Africa